We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Roche announced that a large, international Phase III study (NO16967) of 627 previously treated patients with advanced colorectal cancer met its primary endpoint of progression-free survival.
Vernalis has begun a Phase I trial of V24343, a cannabinoid type 1 (CB1) antagonist, as a potential treatment for obesity, Type 2 diabetes and related disorders.
Kosan Biosciences has presented results from a dose-escalating, Phase Ib clinical trial of its lead Hsp90 inhibitor, tanespimycin (KOS-953), in combination with bortezomib (Velcade) showing a high degree of antitumor activity and tolerability in patients with multiple myeloma who had previously progressed following treatment with multiple conventional therapies.
Merck and Vertex Pharmaceuticals have announced results of a Phase I clinical trial for MK-0457 (also known as VX-680), an investigational small-molecule inhibitor of Aurora, FLT-3, JAK-2 and BCR-ABL kinases.
Memory Pharmaceuticals announced that the FDA has completed its review of the investigational new drug application (IND) for MEM 3454 and has informed the company that the clinical hold on the development of this drug candidate has been released.
New clinical data presented by Novartis demonstrate that Tasigna (nilotinib) eliminated or significantly reduced the presence of blood cells containing a defective chromosome in approximately half of adult patients with a form of life-threatening leukemia who developed resistance or intolerance to treatment with Glivec (imatinib).
Boehringer Ingelheim Pharmaceuticals has presented results from RE-MODEL, a Phase III, randomized, parallel-group, double-blind, active, controlled study, at the meeting of the American Society of Hematology.